Intravenous (IV) administration of antiepileptic drugs is useful in patients who are unable to take oral medication, and in emergency situations such as seizure clusters (SC), status epilepticus (SE), or when rapid introduction of a new agent is necessary because seizures are uncontrolled on baseline therapy. Lacosamide (LCM), a new anti-epileptic drug with a mechanism of action utilizing the slow inactivation of sodium channels [1], is also available in an IV formulation. Several studies have showed the efficacy of IV LCM in patients with SC or SE.
25
SEP
SEP
0